Comparative Effects of Mediterranean and DASH Diet on Hepatic Function

May 30, 2026 updated by: Maria Aslam, University of Lahore

Comparative Effects of Mediterranean and DASH Diet on Hepatic Function in Patients Suffering From NAFLD

Participants were assigned into three groups Control group recieving general dietary guidelines, Mediterranean diet intervention group DASH dietary intervention group

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Written permission was taken from the ethical board for data collection. After taking informed consent from patients in written form, the researcher used self-administered questionnaire or Performa to gather data. NAFLD patients (both genders) of age 25 to 70 years were included.

  1. Screening:

    The participants eligible under inclusion criteria will be enrolled. The baseline data (weight, height, BMI, waist circumference, LFT's, Lipid profile, blood pressure). The target population between 25-70 years were selected.

  2. Allocation:

    The participants were assigned into three groups; control group was given dietary guidelines followed by medication; one group was given Mediterranean diet (T1) and other group was given DASH diet (T2) along with conventional therapy

  3. Follow up:

The follow up of patient were conducted monthly, all laboratory test (LFT's, Lipid profile, blood pressure) were conducted on 1st and after 8th week. The baseline and post-test study were compared to test hypothesis.

Study Type

Interventional

Enrollment (Actual)

75

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
      • Lahore, Pakistan
        • University of Lahore

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adults (25-70 years) of both genders with BMI (above 25 kg/m2).
  • Fatty liver patients with mild to moderate values of Alanine Transaminase (ALT) level range from mild to moderate (30-100U/L)
  • Fatty liver patients having Aspartate Aminotransferase (AST) level range from mild to moderate (200-600 IU/L).
  • Fatty liver patients having Gamma-Glutamyl Transferase (GGT level range from mild to moderate(120-300 U/L) were included.

Exclusion Criteria:

  • Lactating and pregnant women were not included.
  • Patients who are using any kind of medicine.
  • Adults suffering from critical health conditions, including cancer.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control group
Control group (T0): Participants were given dietary guidelines to manage fatty liver disease followed by medications.
Other: Dietary guidelines for fatty liver
Dietary guidelines for managing fatty liver disease followed by medication for 2 months.
Experimental: Treatment group (T1)
Treatment group (T1): Participants were given Mediterranean diet plan for 2 months.
Other: Mediterranean diet
Mediterranean diet plan consists of vegetables, whole grains, and fruit, extra virgin olive oil, nuts, seeds and legumes.
Experimental: Treatment group (T2)
Treatment group (T2): Participant were given DASH diet plan for 2 months.
Other: DASH diet
DASH diet plan consists of antioxidant foods items i.e. fruits and vegetables lean meat and dairy products (low fat dairy products), nuts, grain.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body Mass Index
Time Frame: 60 days
Body Mass Index (BMI) was computed by dividing weight in kilograms by the square of height in meters (kg/m2).
60 days
Liver Function Test
Time Frame: 60 days
The blood test was used to measure the serum concentrations of ALT, AST, and GGT. Following an overnight fast, 10 ml of venous blood was collected from participants both at baseline and post-intervention.
60 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Lahore

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 12, 2025

Primary Completion (Actual)

January 17, 2026

Study Completion (Actual)

February 20, 2026

Study Registration Dates

First Submitted

May 23, 2026

First Submitted That Met QC Criteria

May 30, 2026

First Posted (Actual)

June 3, 2026

Study Record Updates

Last Update Posted (Actual)

June 3, 2026

Last Update Submitted That Met QC Criteria

May 30, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB-UOL-FAHS/717/2025

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Data will be shared in the form of research articles without the personal information of the participant

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hep A

Clinical Trials on Dietary guidelines for fatty liver

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe